Software/ platforms

Flagship Pioneering announced new appointment

Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry.  She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corporate alliance strategy.

A biologist by training, Kay previously served as Chief Business Officer and Head of Finance at Deep Genomics. Prior roles include serving as Senior Vice President of Corporate Development at Synlogic, Inc., and as Chief Operating Officer for Pfizer’s Inflammation and Immunology Research Unit. Kay joined Flagship Pioneering in early 2023 as an Operating Partner, and as President of Metaphore Biotechnologies, which Flagship launched out of stealth in May.

Partnerships can allow companies to make bigger leaps to unlock new value pools,” said Noubar Afeyan, Ph.D., Founder and CEO, Flagship Pioneering. “I look forward to working with Amanda in her new role to identify and harness these opportunities for our ecosystem.”

“Given the broad potential of our bioplatform companies, and the interest we see from the biopharma industry to partner with Flagship to pursue pioneering innovation, it is the right moment to invest more heavily in our business development function and leader,” said Stephen Berenson, Managing Partner, Flagship Pioneering. “Amanda combines her broad biopharma experience in corporate strategy, operations, business development, and financial planning with a scientist’s outlook and passion, and we’re pleased to have her take on this important role.”

“Bringing teams together across functions and companies to go from an idea to a drug in the clinic has always been the most exciting part of my work,” said Amanda Kay, Chief Business Development Officer, Flagship Pioneering. “I look forward to establishing collaborations across the Flagship ecosystem and the broader biopharma industry to advance Flagship’s multiproduct platforms and position them to have maximum impact for patients.”

Kay’s appointment to Chief Business Development Officer follows several executive appointments to Flagship Pioneering this summer including: David Khougazian as Growth Partner; Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines; and Rupert Vessey as Executive Partner and Chief Scientist.

Related posts

Spinnaker SCA Acquires Accelogix

PR Newswire

Replit Announces Strategic Partnership with Google Cloud

PR Newswire

Bruker Expands dia-PASEF® on the timsTOF 4D Proteomics Platform

Business Wire